Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.

Iyer S, Sam FS, DiPrimio N, Preston G, Verheijen J, Murthy K, Parton Z, Tsang H, Lao J, Morava E, Perlstein EO.

Dis Model Mech. 2019 Nov 11;12(11). pii: dmm040584. doi: 10.1242/dmm.040584.

2.

Drug screens of NGLY1 deficiency in worm and fly models reveal catecholamine, NRF2 and anti-inflammatory-pathway activation as potential clinical approaches.

Iyer S, Mast JD, Tsang H, Rodriguez TP, DiPrimio N, Prangley M, Sam FS, Parton Z, Perlstein EO.

Dis Model Mech. 2019 Nov 4;12(11). pii: dmm040576. doi: 10.1242/dmm.040576.

3.

Disease and Region Specificity of Granulin Immunopositivities in Alzheimer Disease and Frontotemporal Lobar Degeneration.

Mao Q, Wang D, Li Y, Kohler M, Wilson J, Parton Z, Shmaltsuyeva B, Gursel D, Rademakers R, Weintraub S, Mesulam MM, Xia H, Bigio EH.

J Neuropathol Exp Neurol. 2017 Nov 1;76(11):957-968. doi: 10.1093/jnen/nlx085.

4.

Asymmetric pathology in primary progressive aphasia with progranulin mutations and TDP inclusions.

Kim G, Ahmadian SS, Peterson M, Parton Z, Memon R, Weintraub S, Rademaker A, Bigio E, Mesulam MM, Geula C.

Neurology. 2016 Feb 16;86(7):627-36. doi: 10.1212/WNL.0000000000002375. Epub 2016 Jan 20.

Supplemental Content

Loading ...
Support Center